Thursday, April 23, 2015

Asterias Biotherapeutics - New All Time High

Asterias Biotherapeutics (AST) is the Barchart Chart of the Day.  The medical products company has a Trend Spotter buy signal, a Weighted Alpha of 60.00+ and gained 264.44% in the last year.

The Chart of the Day belongs to Asterias Biotherapeutics (AST).  I found the stock by sorting the All Time High list for the stocks with the best technical buy signals then used the Flipchart function to review the charts.  Since the Trend Spotter signaled a by in 4/8 the stock gained 73.22%.

Asterias Biotherapeutics, Inc. is a biotechnology company. It is focused on the field of regenerative medicine. The Company's technologies center on stem cells capable of becoming all of the cell types in the human body, a property called pluripotency. It develops therapies based on pluripotent stem cells to treat diseases or injuries in a variety of medical fields, with an initial focus on the therapeutic areas of neurology and oncology.

 The status of Barchart's Opinion trading systems are listed below.  Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates.  The indicator numbers shown below therefore may not match what you see live on the web site when you read this report.

Barchart technical indicators:

  • 100% Barchart technical buy signals
  • Trend Spotter buy signal
  • Above its 20, 50 and 100 day moving averages
  • 11 new highs and up 66.50% in the last month
  • Relative Strength Index 80.77%
  • Barchart computes a technical support level at 10.41
  • Recently traded at 13.41 with a 50 day moving average of 6.69
Fundamental factors:
  • Market Cap $414.37 million
  • Revenue expected to grow 345.70% this year and another 4.50% next year
  • Earnings estimated to increase by 6.50% this year but no projections are made for future periods
  • The lone analyst following the stock has it a buy
This stock has shot up fast so use a trailing stop loss 10% below its recent his to preserve gains.

No comments:

Post a Comment